Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: Dual injection of low-molecular-weight and macromolecular MR contrast media

Radiology

Volumn 257, Issue 2, 2010, Pages 342-352

  Lemasson, Benjamin ^a,b   Serduc, Raphaël ^c   Maisin, Cécile ^a   Bouchet, Audrey ^c   Coquery, Nicolas ^a   Robert, Philippe ^e   Duc, Géraldine Le ^c   Troprès, Irène ^d   Rémy, Chantal ^a   Barbier, Emmanuel L ^a,b  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b Oncodesign Biotechnology   (France)

^c EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

^d UNIV GRENOBLE ALPES   (France)

^e Laboratoire Guerbet   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOTERATE MEGLUMINE; P 846; SORAFENIB; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GLIOSARCOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; RAT; STATISTICAL ANALYSIS; STUDENT T TEST;

ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BENZENESULFONATES; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GLIOMA; HETEROCYCLIC COMPOUNDS; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE IMAGING; MALE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; PYRIDINES; RANDOM ALLOCATION; RATS;

EID: 77958581311     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10092343     Document Type: Article

References (35)

1. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21(21):2683-2710. (Pubitemid 350070717)
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23(10):2411-2422. (Pubitemid 46218735)
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62.
4. Combs SE. Radiation therapy. Recent Results Cancer Res 2009;171:125-140.
5. Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009;29(5):1125-1133.
6. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95. (Pubitemid 46075199)
7. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multi-forme. J Magn Reson Imaging 2002;15(3):233-240. (Pubitemid 34195118)
8. Seshadri M, Ciesielski MJ. MRI-based characterization of vascular disruption by 5,6- dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab 2009;29(8):1373-1382.
9. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to anti-angiogenic therapy. Nat Rev Clin Oncol 2009;6(6):327-338.
10. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging 2007;26(2):235-249.
11. Nakata H, Yoshimine T, Murasawa A, et al. Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats. Acta Neurochir (Wien) 1995;136(1-2):82-86; discussion 86-87.
12. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 2002;9(4):683-688.
13. Plowman PN. Stereotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg 1999;13(3):256-264.
14. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008;10(1):166-177.
15. Serduc R, Vérant P, Vial J-C, et al. In vivo two-photon microscopy study of short-term effects of microbeam irradiation on normal mouse brain microvasculature. Int J Radiat Oncol Biol Phys 2006;64(5):1519-1527.
16. Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006;66(3):860-866. (Pubitemid 44436715)
17. Yuan H, Goetz DJ, Gaber MW, Issekutz AC, Merchant TE, Kiani MF. Radiation-induced upregulation of adhesion molecules in brain microvasculature and their modulation by dexamethasone. Radiat Res 2005;163(5):544-551. (Pubitemid 41490650)
18. Rebeles F, Fink J, Anzai Y, Maravilla KR. Blood-brain barrier imaging and therapeutic potentials. Top Magn Reson Imaging 2006;17(2):107-116. (Pubitemid 46050573)
19. Veeravagu A, Hou LC, Hsu AR, et al. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol Res 2008;30(9):952-959.
20. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7(4):496-501.
21. Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29(6):1300-1307.
22. Raatschen H-J, Simon GH, Fu Y, et al. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008;247(2):391-399.
23. Benda P, Someda K, Messer J, Sweet WH. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 1971;34(3):310-323.
24. Regnard P, Le Duc G, Bräuer-Krisch E, et al. Irradiation of intracerebral 9L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: balance between curing and sparing. Phys Med Biol 2008;53(4):861-878. (Pubitemid 351238110)
25. Bräuer-Krisch E, Requardt H, Brochard T, et al. New technology enables high precision multislit collimators for microbeam radiation therapy. Rev Sci Instrum 2009;80(7):074301.
26. Siegbahn EA, Stepanek J, Bräuer-Krisch E, Bravin A. Determination of dosimetrical quantities used in microbeam radiation therapy (MRT) with Monte Carlo simulations. Med Phys 2006;33(9):3248-3259. (Pubitemid 44327427)
27. Peldschus K, Hamdorf M, Robert P, et al. Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadolinium-based contrast agent P846 in comparison with gadoterate meglumine in rabbits at 1.5 Tesla and 3.0 Tesla. Invest Radiol 2008;43(12):837-842.
28. Heilmann M, Vautier J, Robert P, Volk A. In vitro setup to study permeability characteristics of contrast agents by MRI. Contrast Media Mol Imaging 2009;4(2):66-72.
29. Vautier J, Heilmann M, Dimicoli JL, Volk A. Characterization of an experimental setup to study in vitro permeability properties of macromolecular contrast agents by DCE-MRI [abstr]. In: Proceedings of the Fifteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2007;969.
30. Bloembergen N, Morgan L. Proton relaxation times in paramagnetic solution. J Chem Phys 1961;34(3):842-850.
31. Fries P, Runge VM, Bücker A, et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model. Invest Radiol 2009;44(4):200-206.
32. Beaumont M, Lemasson B, Farion R, Segebarth C, Rémy C, Barbier EL. Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI. J Cereb Blood Flow Metab 2009;29(10):1714-1726.
33. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24): 11851-11858. (Pubitemid 46094197)
34. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med 1991;17(2):357-367.
35. Diserbo M, Agin A, Lamproglou I, et al. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can J Physiol Pharmacol 2002; 80(7):670-678. (Pubitemid 35430404)